{Reference Type}: Journal Article
{Title}: Remyelination-oriented clemastine treatment attenuates neuropathies of optic nerve and retina in glaucoma.
{Author}: Liu K;Yang Y;Wu Z;Sun C;Su Y;Huang N;Wu H;Yi C;Ye J;Xiao L;Niu J;
{Journal}: Glia
{Volume}: 72
{Issue}: 9
{Year}: 2024 09 3
{Factor}: 8.073
{DOI}: 10.1002/glia.24543
{Abstract}: As one of the top causes of blindness worldwide, glaucoma leads to diverse optic neuropathies such as degeneration of retinal ganglion cells (RGCs). It is widely accepted that the level of intraocular pressure (IOP) is a major risk factor in human glaucoma, and reduction of IOP level is the principally most well-known method to prevent cell death of RGCs. However, clinical studies show that lowering IOP fails to prevent RGC degeneration in the progression of glaucoma. Thus, a comprehensive understanding of glaucoma pathological process is required for developing new therapeutic strategies. In this study, we provide functional and histological evidence showing that optic nerve defects occurred before retina damage in an ocular hypertension glaucoma mouse model, in which oligodendroglial lineage cells were responsible for the subsequent neuropathology. By treatment with clemastine, an Food and Drug Administration (FDA)-approved first-generation antihistamine medicine, we demonstrate that the optic nerve and retina damages were attenuated via promoting oligodendrocyte precursor cell (OPC) differentiation and enhancing remyelination. Taken together, our results reveal the timeline of the optic neuropathies in glaucoma and highlight the potential role of oligodendroglial lineage cells playing in its treatment. Clemastine may be used in future clinical applications for demyelination-associated glaucoma.